CMS Decision To Conduct Provenge NCA Could Be "Chilling To Future Innovation," BIO's Greenwood Says
This article was originally published in The Pink Sheet Daily
Executive Summary
BIO CEO Jim Greenwood discusses his views on the Medicare national coverage analysis for Dendreon's prostate cancer immunotherapy Provenge with "The Pink Sheet" DAILY.